The Effect of PC945 on Aspergillus or Candida Lung Infections in Patients With Asthma or Chronic Respiratory Diseases

Stopped The study is being terminated early as a result of the coronavirus (COVID-19) outbreak.

Conditions

• Asthma
• Respiratory Candidiasis
• Respiratory Aspergillosis
• COPD
• Bronchiectasis

Interventions

• DRUG: PC945
• DRUG: Placebo

Sponsor

Pulmocide Ltd